Paul Clement

1.4k total citations
24 papers, 441 citations indexed

About

Paul Clement is a scholar working on Oncology, Epidemiology and Cancer Research. According to data from OpenAlex, Paul Clement has authored 24 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Epidemiology and 5 papers in Cancer Research. Recurrent topics in Paul Clement's work include Neuroendocrine Tumor Research Advances (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Neuroblastoma Research and Treatments (3 papers). Paul Clement is often cited by papers focused on Neuroendocrine Tumor Research Advances (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Neuroblastoma Research and Treatments (3 papers). Paul Clement collaborates with scholars based in Belgium, Netherlands and United States. Paul Clement's co-authors include Hans Wildiers, Johan Menten, Herlinde Dumez, Joseph Schoenaers, Patrick Schöffski, Jean‐Pierre Lobelle, Benoit Beuselinck, Jacques Gielen, Koen Milisen and Kristiaan Nackaerts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Paul Clement

24 papers receiving 431 citations

Peers

Paul Clement
Michael A. Garcia United States
Magdalena Rutkowska Poland
Richard Tunkel United States
Kenneth Gaines United States
Gisele M. Hankins United States
Elena Fagnoni Italy
J.-B. Morvan France
O Roikjær Denmark
Ali Siddiqui United States
Marco A. Mascarella Canada
Michael A. Garcia United States
Paul Clement
Citations per year, relative to Paul Clement Paul Clement (= 1×) peers Michael A. Garcia

Countries citing papers authored by Paul Clement

Since Specialization
Citations

This map shows the geographic impact of Paul Clement's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Clement with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Clement more than expected).

Fields of papers citing papers by Paul Clement

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Clement. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Clement. The network helps show where Paul Clement may publish in the future.

Co-authorship network of co-authors of Paul Clement

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Clement. A scholar is included among the top collaborators of Paul Clement based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Clement. Paul Clement is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dupont, Patrick, Stefan Sunaert, Steven De Vleeschouwer, et al.. (2025). Increased functional network segregation in glioma patients posttherapy: A neurological compensatory response or catastrophe for cognition?. Network Neuroscience. 9(2). 743–760. 2 indexed citations
2.
Blommaert, Jeroen, Patrick Dupont, Stefan Sunaert, et al.. (2025). Structural Network Hubs as Potential Organs at Risk in Glioma Patients After Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 122(3). 631–642. 2 indexed citations
3.
Laureano, Raquel S., Isaure Vanmeerbeek, Jenny Sprooten, et al.. (2024). Trial watch: anticancer vaccination with dendritic cells. OncoImmunology. 13(1). 2412876–2412876. 15 indexed citations
4.
Pauwels, Elin, Vincent Vandecaveye, Wies Deckers, et al.. (2023). Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Research. 13(1). 53–53. 9 indexed citations
5.
Vandecaveye, Vincent, Annouschka Laenen, Wies Deckers, et al.. (2023). Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI. Therapeutic Advances in Medical Oncology. 15. 2633869–2633869. 1 indexed citations
6.
Kinget, Lisa, Oliver Bechter, Kevin Punie, et al.. (2021). Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Current Oncology. 28(5). 3227–3239. 3 indexed citations
7.
Wildiers, Hans, Kevin Punie, Benoit Beuselinck, et al.. (2021). Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. Journal of Cancer Research and Clinical Oncology. 147(4). 1041–1048. 1 indexed citations
8.
Licitra, Lisa, Robert I. Haddad, Caroline Even, et al.. (2019). EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6012–6012. 31 indexed citations
9.
Cann, Thomas Van, Patrick Schöffski, Paul Clement, et al.. (2017). Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clinica Belgica. 73(2). 100–109. 40 indexed citations
10.
Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, et al.. (2017). Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study. Annals of Oncology. 28. v372–v372. 24 indexed citations
11.
Cann, Thomas Van, Annelies Verbiest, Paul Clement, et al.. (2017). Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Supportive Care in Cancer. 26(3). 869–878. 42 indexed citations
12.
Koole, Michel, Christelle Terwinghe, Kristof Baete, et al.. (2016). Dynamische und statische 68Ga-DOTATOC-PET/CT bei Patienten mit NET. Nuklearmedizin - NuclearMedicine. 55(3). 104–114. 4 indexed citations
13.
Verheecke, Magali, M Halaška, Christianne Lok, et al.. (2014). Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. European Journal of Cancer. 50(8). 1462–1471. 37 indexed citations
14.
Clement, Paul, et al.. (2013). The Use of High Dosages of Transdermal Buprenorphine for Pain Management in Palliative Cancer Patients: A Case Study. Case Reports in Oncology. 6(1). 169–173. 3 indexed citations
15.
Wildiers, Hans, et al.. (2009). Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care. Journal of Pain and Symptom Management. 38(1). 124–133. 61 indexed citations
16.
Wolter, Pascal, Hans Wildiers, Dirk Vanderschueren, et al.. (2009). Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR). Journal of Clinical Oncology. 27(15_suppl). 3565–3565. 7 indexed citations
17.
Clement, Paul, Pascal Wolter, Brigitte Decallonne, et al.. (2008). Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. Journal of Clinical Oncology. 26(15_suppl). 16145–16145. 9 indexed citations
18.
Lybaert, Willem, Hans Wildiers, Patrick Neven, et al.. (2006). Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data. Breast Cancer Research and Treatment. 100. 9 indexed citations
19.
Clement, Paul, Herlinde Dumez, Patrick Schöffski, et al.. (2006). Ecteinascidin‐743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients. Sarcoma. 2006(1). 56282–56282. 22 indexed citations
20.
Lybaert, Willem, Hans Wildiers, Patrick Neven, et al.. (2006). Neoadjuvant capecitabine (X), docetaxel (T)±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data from a multicentre phase II study. European Journal of Cancer Supplements. 4(2). 157–158. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Garcia Breakdown of academic impact, for papers by Magdalena Rutkowska Breakdown of academic impact, for papers by Richard Tunkel Breakdown of academic impact, for papers by Kenneth Gaines Breakdown of academic impact, for papers by Gisele M. Hankins Breakdown of academic impact, for papers by Elena Fagnoni Breakdown of academic impact, for papers by J.-B. Morvan Breakdown of academic impact, for papers by O Roikjær Breakdown of academic impact, for papers by Ali Siddiqui Breakdown of academic impact, for papers by Marco A. Mascarella
Rankless by CCL
2026